Table 3.
VEGF haplotypes and breast cancer risk in premenopausal subjects
| Haplotypea | Pre menopausal cases (%) n = 114 |
Pre menopausal controls (%) n = 150 |
OR (95%CI) | p value |
|---|---|---|---|---|
| AICGCC | 29.0 | 24.5 | 1 (Reference) | |
| CDTCCC | 20.6 | 28.5 | 0.65 (0.43–0.99) | 0.04 |
| CDTGCC | 25.0 | 26.3 | 0.95 (0.64–1.42) | 0.81 |
| AICGTC | 9.0 | 9.9 | 0.90 (0.50–1.64) | 0.73 |
| AICGCT | 3.1 | 1.4 | 2.23 (0.67–7.43) | 0.18 |
| AICGTT | 3.2 | 1.5 | 2.27 (0.69–7.51) | 0.16 |
| CDTCCT | 3.3 | 2.1 | 1.87 (0.46–7.56) | 0.38 |
Significant p values are shown in bold
OR odds ratio, CI confidence interval
aIn order of −2578C/A, −2549I/D, −460T/C, +405C/G, −7C/T and +936C/T